Efficacy and Safety of Tildrakizumab for Treatment of Moderate-to-Severe Scalp Psoriasis in Patients with Obesity Over 52 Weeks

• by Howard L. Sofen, Ranga Gogineni, Tushar Nishandar, Jerry Bagel

• May 9, 2026

A Narrative Review: Do Systemic Drugs Used in the Treatment of Psoriatic Disease Affect Alzheimer’s Disease?

• by Jin-Hui Chen, Tsen-Fang Tsai

• May 2, 2026

Effectiveness, Safety, and Drug Survival of Bimekizumab in Chronic Plaque Psoriasis over 2 Years: Real-World Experience from Northern Italy

• by Zeno Fratton, Stefano Bighetti, Luca Bettolini, Marina Venturini, Mariateresa Rossi, Andrea Carugno, Nicola Zerbinati, Giuseppe Stinco, Enzo Errichetti

• June 28, 2026

Psoriasis–AD Switching May Mimic Treatment Failure

Recognizing sustained switches between the two diseases can prevent premature discontinuation of effective biologics and point toward Janus kinase inhibitors, a 148-patient cohort suggests.

• by Andrea Surnit

• June 15, 2026

• 4 min